NRIX241220C17500
- 5.80
- 0.000.00%
Nurix Therapeutics Newsroom
Needham Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $29
Promising Efficacy and Safety of Nurix Therapeutics' NX-5948 Justifies Buy Rating
Nurix Therapeutics Price Target Maintained With a $29.00/Share by Needham
Nurix Therapeutics Analyst Ratings
UBS Initiates Coverage On Nurix Therapeutics With Buy Rating, Announces Price Target of $35
Barclays Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $31
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $29 to $41
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $29 to $41
Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Ascendis Pharma (ASND)
Nurix Therapeutics Analyst Ratings
Promising Data on Nurix Therapeutics' NX-5948 Supports Buy Rating for Waldenstrom's Macroglobulinemia Treatment
Oppenheimer Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $35
J.P. Morgan Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Cuts Target Price to $31
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $29 to $35
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NRIX) and PTC Therapeutics (PTCT)
Optimistic Buy Rating for Nurix Therapeutics Based on Promising NX-5948 Drug Candidate and Strategic Collaborations
Nurix Therapeutics Is Maintained at Outperform by RBC Capital
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $26 to $35
RBC Trims Price Target on Nurix Therapeutics to $26 From $27, Keeps Outperform, Speculative Risk
Truist Financial Remains a Buy on Nurix Therapeutics (NRIX)